Autoimmune disease treatments

Abstract

There are provided, inter alia, methods and compositions to treat autoimmune disease including invasiveness of fibroblast-like synoviocytes in rheumatoid arthritis.

What is claimed is: 
     
       1. A method of decreasing inflammation in a synovium of a subject in need thereof, the method comprising administering to the subject an effective amount of a PTPRK antagonist, wherein the PTPRK antagonist is an anti-PTPRK inhibitory nucleic acid capable of inhibiting PTPRK expression and wherein the PTPRK antagonist is delivered by contacting a fibroblast-like synoviocyte in the subject. 
     
     
       2. The method of  claim 1 , wherein said subject comprises fibroblast-like synoviocytes that express high levels of PTPRK relative to a standard control. 
     
     
       3. The method of  claim 2 , wherein said subject has rheumatoid arthritis. 
     
     
       4. The method of  claim 1  wherein said anti-PTPRK inhibitory nucleic acid has at least 90% sequence identity to an at least 10 nucleotide contiguous sequence of SEQ ID NO:1, SEQ ID NO:2 or a complementary sequence thereof. 
     
     
       5. The method of  claim 1 , further comprising treating an autoimmune disease in said subject. 
     
     
       6. The method of  claim 5 , wherein said autoimmune disease is a fibroblast mediated disease, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison's disease, Vitiligo, asthma, scleroderma, systemic sclerosis, or allergic asthma. 
     
     
       7. The method of  claim 2 , wherein said PTPRK antagonist decreases TNF activity, IL-1 activity or PDGF activity in said fibroblast-like synoviocyte.